Close the Chinese Drug Back Door, Bring Medicine Production Back to the U.S.

Originally published by Breitbart

America’s dependence on foreign drug ingredients is a national security and safety issue that is hiding in plain sight.

For years, Washington outsourced the very building blocks of our medicines to cut-rate producers abroad, especially in China. That was a bargain with fine print: quality we can’t verify, leverage we don’t control, and risks that land directly in American veins. The Trump administration was right to call this out and push for a tougher line on Chinese Communist Party (CPP) leadership and strategic decoupling.

Now we need to finish the job by rebuilding U.S. manufacturing and shutting the loopholes that let unsafe products slip through.

Popular and common weight-loss drugs are a prime example. They show both the promise and peril. But the weight-loss boom has opened a back door, and Beijing has walked straight through it. While patients line up for brand-name shots, a shadow supply chain sprang up: copycats of drugs built on Chinese precursors that should never have cleared our ports. That isn’t “access.” It’s an under-the-radar patient pipeline that gambles with American health and our national security.

To read the full article, click here.